Anti-CTLA-4 therapy results in higher CD4+ICOShiT cell frequency and IFN-γ levels in both nonmalignant and malignant prostate tissues-Reference-Cited by-同舟云学术

Anti-CTLA-4 therapy results in higher CD4+ICOShiT cell frequency and IFN-γ levels in both nonmalignant and malignant prostate tissues

Published:2009-02-06 Issue:8 Volume:106 Page:2729-2734
ISSN:0027-8424
Container-title:Proceedings of the National Academy of Sciences
language:en
Short-container-title:PNAS

Author:

Chen Hong,Liakou Chrysoula I.,Kamat Ashish,Pettaway Curtis,Ward John F.,Tang Derek Ng,Sun Jingjing,Jungbluth Achim A.,Troncoso Patricia,Logothetis Christopher,Sharma Padmanee

Publisher

Proceedings of the National Academy of Sciences

Subject

Multidisciplinary

Reference35 articles.

1. CTLA-4 can function as a negative regulator of T cell activation

2. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation.

3. CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells.

4. Enhancement of Antitumor Immunity by CTLA-4 Blockade

5. Combination Immunotherapy of B16 Melanoma Using Anti–Cytotoxic T Lymphocyte–Associated Antigen 4 (Ctla-4) and Granulocyte/Macrophage Colony-Stimulating Factor (Gm-Csf)-Producing Vaccines Induces Rejection of Subcutaneous and Metastatic Tumors Accompanied by Autoimmune Depigmentation

Cited by 182 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Combination anti-PD-1 and anti-CTLA-4 therapy generates waves of clonal responses that include progenitor-exhausted CD8+ T cells;Cancer Cell;2024-09

2. Toxicity in the era of immune checkpoint inhibitor therapy;Frontiers in Immunology;2024-08-23

3. Challenges of targeting tumor microenvironment in prostate cancer;New Updates in Tumor Microenvironment [Working Title];2024-08-14

4. Peripheral Blood TCRβ Repertoire, IL15, IL2 and Soluble Ligands for NKG2D Activating Receptor Predict Efficacy of Immune Checkpoint Inhibitors in Lung Cancer;Cancers;2024-08-08

5. Harnessing the capacity of phytochemicals to enhance immune checkpoint inhibitor therapy of cancers: A focus on brain malignancies;Cancer Letters;2024-07